Yes I suspect your line of thinking is similar to my own. PR is a salesman and would expect big pharma BDMs to the bridge the gap within their distribution channels. They will have supporting material no doubt from the supporting P3 substreams now proposed. Nevertheless BDMs and word of mouth on PPS's being a DMOAD may still be of limited relevance on any future deal given its not why it will be approved for use. So how PPS is initially pitched (sold) becomes the billion dollar question.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.010(2.44%) |
Mkt cap ! $166.9M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 42.0¢ | 40.0¢ | $168.2K | 411.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 50665 | 2 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |